ممانتین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "ممانتین" in Persian language version.

refsWebsite
Global rank Persian rank
4th place
5th place
2nd place
2nd place
3,258th place
1,207th place
low place
low place
low place
low place
6,663rd place
4,237th place

aspetjournals.org

molpharm.aspetjournals.org

doi.org

  • Mount C, Downton C (July 2006). "Alzheimer disease: progress or profit?". Nature Medicine. 12 (7): 780–4. doi:10.1038/nm0706-780. PMID 16829947.
  • Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC 5129475. PMID 27527376.
  • Mount C, Downton C (ژوئیه ۲۰۰۶). «Alzheimer disease: progress or profit?». Nat Med. ۱۲ (۷): ۷۸۰–۴. doi:10.1038/nm0706-780. PMID 16829947.
  • Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S (۲۰۱۳). «In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)». Psychopharmacology. ۲۲۸ (۴): ۶۳۳–۴۰. doi:10.1007/s00213-013-3067-z. PMID 23525525.
  • Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA (۲۰۱۰). «A single-blinded case-control study of memantine in severe obsessive-compulsive disorder». Journal of Clinical Psychopharmacology. ۳۰ (۱): ۳۴–۹. doi:10.1097/JCP.0b013e3181c856de. PMID 20075645.
  • Schwartz، Thomas L.؛ Siddiqui، Umar A.؛ Raza، Shafi (۲۰۱۲). «Memantine as an Augmentation Therapy for Anxiety Disorders». Case Reports in Psychiatry. ۲۰۱۲: ۱–۳. doi:10.1155/2012/749796.
  • Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW (۲۰۰۱). «The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans». Psychopharmacology. ۱۵۷ (۱): ۱–۱۰. doi:10.1007/s002130100739. PMID 11512037.
  • Green AJ (February 2009). "Understanding pseudo. The symptoms are real, the cause is unclear". Neurology. 72 (19): 1626–7. doi:10.1212/01.wnl.0000345879.39454.68. PMID 19246422.
  • Morris H, Wallach J (۲۰۱۴). «From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis. ۶ (۷–۸): ۶۱۴–۳۲. doi:10.1002/dta.1620. PMID 24678061.
  • Parsons، C.G.؛ Danysz، W.؛ Quack، G. (۱۹۹۹). «Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data». Neuropharmacology. ۳۸ (۶): ۷۳۵–۶۷. doi:10.1016/S0028-3908(99)00019-2. PMID 10465680.
  • Swedberg MD, Ellgren M, Raboisson P (۲۰۱۴). «mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties». The Journal of Pharmacology and Experimental Therapeutics. ۳۴۹ (۱): ۱۵۵–۶۴. doi:10.1124/jpet.113.211185. PMID 24472725.
  • Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P (۱۹۸۹). «Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex». Eur.J.Pharmacol. ۱۶۶ (۳): ۵۸۹–۵۹۰. doi:10.1016/0014-2999(89)90384-1. PMID 2680528.
  • Chen HS, Lipton SA (۱۵ فوریه ۱۹۹۷). «Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism». J. Physiol. (Lond.). ۴۹۹ (Pt ۱): ۲۷–۴۶. doi:10.1113/jphysiol.1997.sp021909. PMC 1159335. PMID 9061638.
  • Rogawski، MA؛ Wenk GL (۲۰۰۳). «The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease». CNS Drug Rev. ۹ (۳): ۲۷۵–۳۰۸. doi:10.1111/j.1527-3458.2003.tb00254.x. PMID 14530799.
  • Robinson، DM؛ Keating GM (۲۰۰۶). «Memantine: a review of its use in Alzheimer's disease». Drugs. ۶۶ (۱۱): ۱۵۱۵–۳۴. doi:10.2165/00003495-200666110-00015. PMID 16906789.
  • Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG (۲۰۰۱). «The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner». Neuroscience Letters. ۳۰۶ (۱–۲): ۸۱–۴. doi:10.1016/S0304-3940(01)01872-9. PMID 11403963.
  • Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (مارس ۲۰۰۵). «Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons». J Pharmacol Exp Ther. ۳۱۲ (۳): ۱۱۹۵–۲۰۵. doi:10.1124/jpet.104.077172. PMID 15522999.
  • Seeman P, Caruso C, Lasaga M (فوریه ۲۰۰۸). «Memantine agonist action at dopamine D2High receptors». Synapse. ۶۲ (۲): ۱۴۹–۵۳. doi:10.1002/syn.20472. PMID 18000814.
  • Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (آوریل ۲۰۰۴). «Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine». Eur J Neurosci. ۱۹ (۸): ۲۲۱۲–۲۰. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047.

jneurosci.org

jphysiol.org

nice.org.uk

nih.gov

ncbi.nlm.nih.gov

  • Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC 5129475. PMID 27527376.
  • Mount C, Downton C (ژوئیه ۲۰۰۶). «Alzheimer disease: progress or profit?». Nat Med. ۱۲ (۷): ۷۸۰–۴. doi:10.1038/nm0706-780. PMID 16829947.
  • Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S (۲۰۱۳). «In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)». Psychopharmacology. ۲۲۸ (۴): ۶۳۳–۴۰. doi:10.1007/s00213-013-3067-z. PMID 23525525.
  • Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA (۲۰۱۰). «A single-blinded case-control study of memantine in severe obsessive-compulsive disorder». Journal of Clinical Psychopharmacology. ۳۰ (۱): ۳۴–۹. doi:10.1097/JCP.0b013e3181c856de. PMID 20075645.
  • Hosenbocus S, Chahal R (۲۰۱۳). «Memantine: a review of possible uses in child and adolescent psychiatry». Journal of the Canadian Academy of Child and Adolescent Psychiatry. ۲۲ (۲): ۱۶۶–۷۱. PMC 3647634. PMID 23667364.
  • Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW (۲۰۰۱). «The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans». Psychopharmacology. ۱۵۷ (۱): ۱–۱۰. doi:10.1007/s002130100739. PMID 11512037.
  • Morris H, Wallach J (۲۰۱۴). «From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs». Drug Testing and Analysis. ۶ (۷–۸): ۶۱۴–۳۲. doi:10.1002/dta.1620. PMID 24678061.
  • Parsons، C.G.؛ Danysz، W.؛ Quack، G. (۱۹۹۹). «Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data». Neuropharmacology. ۳۸ (۶): ۷۳۵–۶۷. doi:10.1016/S0028-3908(99)00019-2. PMID 10465680.
  • Swedberg MD, Ellgren M, Raboisson P (۲۰۱۴). «mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties». The Journal of Pharmacology and Experimental Therapeutics. ۳۴۹ (۱): ۱۵۵–۶۴. doi:10.1124/jpet.113.211185. PMID 24472725.
  • Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P (۱۹۸۹). «Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex». Eur.J.Pharmacol. ۱۶۶ (۳): ۵۸۹–۵۹۰. doi:10.1016/0014-2999(89)90384-1. PMID 2680528.
  • Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (۱ نوامبر ۱۹۹۲). «Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity». J. Neurosci. ۱۲ (۱۱): ۴۴۲۷–۳۶. PMID 1432103.
  • Chen HS, Lipton SA (۱۵ فوریه ۱۹۹۷). «Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism». J. Physiol. (Lond.). ۴۹۹ (Pt ۱): ۲۷–۴۶. doi:10.1113/jphysiol.1997.sp021909. PMC 1159335. PMID 9061638.
  • Rogawski، MA؛ Wenk GL (۲۰۰۳). «The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease». CNS Drug Rev. ۹ (۳): ۲۷۵–۳۰۸. doi:10.1111/j.1527-3458.2003.tb00254.x. PMID 14530799.
  • Robinson، DM؛ Keating GM (۲۰۰۶). «Memantine: a review of its use in Alzheimer's disease». Drugs. ۶۶ (۱۱): ۱۵۱۵–۳۴. doi:10.2165/00003495-200666110-00015. PMID 16906789.
  • Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG (۲۰۰۱). «The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner». Neuroscience Letters. ۳۰۶ (۱–۲): ۸۱–۴. doi:10.1016/S0304-3940(01)01872-9. PMID 11403963.
  • Buisson B, Bertrand D (۱ مارس ۱۹۹۸). «Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor». Mol Pharmacol. ۵۳ (۳): ۵۵۵–۶۳. PMID 9495824.
  • Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (مارس ۲۰۰۵). «Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons». J Pharmacol Exp Ther. ۳۱۲ (۳): ۱۱۹۵–۲۰۵. doi:10.1124/jpet.104.077172. PMID 15522999.
  • Seeman P, Caruso C, Lasaga M (فوریه ۲۰۰۸). «Memantine agonist action at dopamine D2High receptors». Synapse. ۶۲ (۲): ۱۴۹–۵۳. doi:10.1002/syn.20472. PMID 18000814.
  • Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (آوریل ۲۰۰۴). «Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine». Eur J Neurosci. ۱۹ (۸): ۲۲۱۲–۲۰. doi:10.1111/j.0953-816X.2004.03297.x. PMID 15090047.

pubmed.ncbi.nlm.nih.gov

  • Mount C, Downton C (July 2006). "Alzheimer disease: progress or profit?". Nature Medicine. 12 (7): 780–4. doi:10.1038/nm0706-780. PMID 16829947.
  • Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC 5129475. PMID 27527376.
  • Green AJ (February 2009). "Understanding pseudo. The symptoms are real, the cause is unclear". Neurology. 72 (19): 1626–7. doi:10.1212/01.wnl.0000345879.39454.68. PMID 19246422.